The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult). These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes. An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease. In the last several years, global market of Microbiome Therapeutics developed rapidly, with an average growth rate of 98%. In 2017, Global Market Size of Microbiome Therapeutics is nearly 14 M USD. For developing product, there are 2 products in Phase 3, 7 products in Phase 2, 8 products in Phase 1 and 17 products in Preclinical. The total investment for Microbiome Therapeutics developing is around 293 M USD in 2017. The Application of Microbiome Therapeutics includes CDI, IBD, Orphan Drug, Immuno-oncology and Others, and the proportion of R&D Investmen for CDI in 2016 is about 52%, and the proportion is in Increase trend from 2012 to 2016. The global Microbiome Therapeutics market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Microbiome Therapeutics market based on company, product type, end user and key regions. This report studies the global market size of Microbiome Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Microbiome Therapeutics in these regions. This research report categorizes the global Microbiome Therapeutics market by top players/brands, region, type and end user. This report also studies the global Microbiome Therapeutics market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors. The following manufacturers are covered in this report, with sales, revenue, market share for each company: Seres Therapeutics Assembly Biosciences Synthetic Biologics Interxon PureTech Synlogic Enterome BioScience 4D Pharma Second Genome AOBiome C3 Jian Rebiotix MicroBiome Therapeutics LLC Metabiomics Ritter Pharmaceuticals Symberix OpenBiome Azitra Symbiotix Biotherapies Osel Metabogen Market size by Product Type I Type II Market size by End User Inflammatory Bowel Disease (IBD) Orphan Drug Immuno-oncology Others Market size by Region North America United States Canada Mexico Asia-Pacific China India Japan South Korea Australia Indonesia Singapore Malaysia Philippines Thailand Vietnam Europe Germany France UK Italy Spain Russia Central & South America Brazil Rest of Central & South America Middle East & Africa GCC Countries Turkey Egypt South Africa The study objectives of this report are: To study and analyze the global Microbiome Therapeutics market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025. To understand the structure of Microbiome Therapeutics market by identifying its various subsegments. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). Focuses on the key global Microbiome Therapeutics companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development. To project the value and sales volume of Microbiome Therapeutics submarkets, with respect to key regions. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. In this study, the years considered to estimate the market size of Microbiome Therapeutics are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025 This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Microbiome Therapeutics market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources. For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents 1 Study Coverage 1.1 Microbiome Therapeutics Product 1.2 Market Segments 1.3 Key Manufacturers Covered 1.4 Market by Type 1.4.1 Global Microbiome Therapeutics Market Size Growth Rate by Product 1.4.2 Type I 1.4.3 Type II 1.5 Market by End User 1.5.1 Global Microbiome Therapeutics Market Size Growth Rate by End User
